On 10 February 2026, the SPIOMET4HEALTH consortium held its latest review meeting with the European Commission, marking an important milestone as the project enters its final year.
The meeting brought together representatives of the consortium, the Project Officer and two external experts, who assessed the progress achieved during the reporting period and discussed the priorities for the months ahead. As the project approaches its completion in December 2026, this review represented the last formal evaluation before the final project review.
Steady progress in a decisive phase
During the meeting, partners presented updates across all work packages. With recruitment completed and follow-up activities finalised, the project has now moved into the data consolidation phase. Clinical data are currently being cleaned, validated and prepared for final statistical analysis. Once this process is completed and the database is locked, the consortium expects to obtain robust results that may confirm the positive potential of the SPIOMET4HEALTH treatment strategy for women with Polycystic Ovary Syndrome (PCOS) — a condition that continues to be underdiagnosed and insufficiently addressed.
The coming months will be dedicated to:
– Finalising data preparation and conducting the statistical analysis.
– Assessing the scientific robustness of the results.
– Evaluating the regulatory and clinical feasibility of the SPIOMET treatment strategy.
– Preparing the ground for potential future implementation pathways.
SPIOMET4HEALTH is now fully focused on delivering high-quality evidence and ensuring that its results can contribute meaningfully to advancing women’s health research in Europe. By combining clinical excellence, regulatory insight, patient-centred perspectives and strong European collaboration, SPIOMET4HEALTH continues to address an unmet need in adolescent and young women’s health.
Constructive dialogue ahead to the final stretch
The Project Officer and the invited experts provided valuable feedback and guidance to support the successful completion of the project. The discussion not only served as a formal assessment point, but also as a strategic moment to align work for the final phase of the project and maximise its scientific and societal impact.
Special emphasis was placed on the detailed timeline of actions planned for the coming months, ensuring that all activities remain fully aligned with the project’s final milestones. This forward-looking discussion was key to guaranteeing a smooth transition towards the final review and the successful closure of the project.
This shift from implementation to analysis marks a critical step in determining the potential of SPIOMET as an innovative, evidence-based therapeutic strategy for women living with PCOS.
The consortium would like to thank the Project Officer and the experts for their continued support and constructive engagement as we move towards the final stage of the project.